Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(Mpz-cre)3Brn transgene insertion 3, Anton Berns MGI:3047148 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 4 of 12 mice die prematurely due to malignant peripheral nerve sheath tumors, 3 of which are 5 months old
|
|
• in 4 of 12 mice
|
|
• in 4 of 12 mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit a decrease in survival rate when the Nf2 and Trp53 alleles are carried in cis as opposed to trans, but live longer than conditional mutants carrying Tg(P0-Cre)2Gth
|
|
• between 3.5 and 13.5 months,19% of mice develop malignant peripheral nerve sheath tumors when the Nf2 and Trp53 alleles are carried in cis
• however, no tumors form in mice when the Nf2 and Trp53 alleles are carried in trans
|
|
• when the Nf2 and Trp53 alleles are carried in trans mice develop osteogenic tumors not restricted to neural crest-derived bone
|
|
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis
|
|
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis
|
|
• when the Nf2 and Trp53 alleles are carried in trans mice develop osteogenic tumors not restricted to neural crest-derived bone
|
|
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis
|
|
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis
|
|
• between 3.5 and 13.5 months,19% of mice develop malignant peripheral nerve sheath tumors when the Nf2 and Trp53 alleles are carried in cis
• however, no tumors form in mice when the Nf2 and Trp53 alleles are carried in trans
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 12% of mice exhibit fibroadenoma in the mammary gland
|
|
• 30% of mice develop osseous metaplasia
|
|
• in 12% in mice
|
|
• 18% of mice develop carcinoma in situ in the kidney
|
|
• 30% of mice develop stromal sarcoma
|
|
• 6% of mice develop neurofibrosarcoma
|
|
• in 6% of mice
|
|
• 6% of mice exhibit odontoma
|
|
• 30% of mice develop osseous metaplasia
(J:63264)
• 6% of mice exhibit odontoma
(J:63264)
• 35% of mice develop schwannomas
(J:92413)
|
|
• 6% of mice develop osteoma
|
|
• 12% of mice exhibit odontoblastic hyperplasia
|
|
• in 6% of mice
|
|
• 6% of mice develop osteoma
|
|
• osteogenic hyperplasia in 47% of mice
|
|
• 82% of mice exhibit Schwann cell hyperplasia
|
|
• 6% of mice develop neurofibrosarcoma
|
|
• 30% of mice develop osseous metaplasia
(J:63264)
• 6% of mice exhibit odontoma
(J:63264)
• 35% of mice develop schwannomas
(J:92413)
|
|
• 18% of mice develop carcinoma in situ in the kidney
|
|
• 53% of mice exhibit renal tubular cell hyperplasia
|
|
• 12% of mice exhibit odontoblastic hyperplasia
|
|
• 12% of mice exhibit odontoblastic hyperplasia
|
|
• in 12% in mice
|
|
• 12% of mice exhibit fibroadenoma in the mammary gland
|
|
• 12% of mice exhibit fibroadenoma in the mammary gland
|
|
• 82% of mice exhibit Schwann cell hyperplasia
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 09/30/2025 MGI 6.24 |
|
|
|
||
